PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
19-Feb-2025 Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East Nyxoah SA.
19-Feb-2025 Strong 2024 performance reflects Straumann Group’s strengths in innovation and execution Straumann Holding AG
18-Feb-2025 Caress Flow Wins Prestigious Award at Inaugural Menopause in Aesthetics Awards Caress Flow
18-Feb-2025 CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators CureVac
18-Feb-2025 LIPOSUCTION FOR LIPOEDEMA: ANAEMIA IS A RISK FACTOR Karl Landsteiner University of Health Sciences
18-Feb-2025 Cambridge Cognition submits FDA Letter of Intent for Cognitive Impairment Assessments in Schizophrenia Cambridge Cognition
18-Feb-2025 European Commission Approves Biocon Biologics’ Ustekinumab Biosimilar Biocon Biologics Ltd
18-Feb-2025 DÜRR NDT GmbH & Co. KG DÜRR NDT GmbH & Co. KG
18-Feb-2025 BC Platforms Appoints Mukhtar Ahmed as Chief Executive Officer to Accelerate Growth and Real-World Data Innovation BC Platforms
18-Feb-2025 NHS data infrastructure must support the research needs of the life sciences sector ABPI
18-Feb-2025 New Research Highlights the Role of Aspirin and Advanced Ultrasound Techniques in Cardiovascular Health Bayer
18-Feb-2025 Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid Sanofi
18-Feb-2025 Siegfried reports continued profitable growth fueled by strong underlying business Siegfried AG
17-Feb-2025 Kromek receives $25.0m under agreement with Siemens Healthineers Kromek Group plc
17-Feb-2025 Sartorius Stedim Biotech releases Universal Registration Document 2024 Sartorius Stedim Biotech SA
17-Feb-2025 Formycon AG informs about recent developments in various biosimilar projects and invites to conference call Formycon AG
17-Feb-2025 Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201 Formycon AG
14-Feb-2025 Nxera Pharma Proposes Changes to its Board of Directors Nxera Pharma
14-Feb-2025 Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024 Nxera Pharma
14-Feb-2025 Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Sanofi